Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Zedira GmbH. (11/30/16). "Press Release: Zedira Receives Funding by the German Government for the Development of Transglutaminase Inhibitors for the Treatment of Diabetic Nephropathy". Darmstadt.

Region Region Germany
Organisations Organisation Zedira GmbH
  Organisation 2 BMBF (Federal Ministry for Education and Research) (DE)
  Group Germany (govt)
Products Product ZED1227 (Zedira / Dr Falk Pharma)
  Product 2 business development (state/region)
Index term Index term Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy
Persons Person Hils, Martin (Zedira 201106 CEO + co-founder before N-Zyme Biotec)
  Person 2 Pasternack, Ralf (Zedira 201106 Managing Director + co-founder before N-Zyme Biotec 200506 Managing Director)

Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years.

The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally bioavailable. Transglutaminase is considered to be a scientifically validated target in certain fibrotic diseases such as diabetic nephropathy. Kidney injury is one of the most severe complications of diabetes.

The funding will allow Zedira to expand its leadership in low-molecular-weight transglutaminase blockers. In fact, Zedira’s ZED1227 is the first transglutaminase blocker ever to be evaluated in clinical trials for celiac disease, and is currently in phase 1b trials. Additionally, the core biotech company has recently developed ZED3197, the first drug candidate to target blood coagulation factor XIII (F13, plasma transglutaminase). This compound (a peptidomimetic) has proved to be a potent anticoagulant without prolonging the bleeding time in an animal model of venous stasis and reperfusion.

About Zedira:

The Darmstadt-based biotech company has a focus on transglutaminase-linked conditions in the arena of autoimmunity, fibrotic disease and thrombosis. The company develops, produces and markets specialized reagents and kits for research and development as well as for clinical diagnostics. Zedira is a portfolio company of the German High-Tech Gründerfonds.


The press release is published by:

Zedira GmbH
Dr Martin Hils,
Dr Ralf Pasternack
Roesslerstr. 83
64293 Darmstadt
Phone: +49 6151 3251-00
Fax: +49 6151 3251-19

© 2016, Zedira GmbH

Record changed: 2017-01-17


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Zedira GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top